Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs i… (NCT07184827) | Clinical Trial Compass
RecruitingPhase 3
Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women
Taiwan348 participantsStarted 2020-10-14
Plain-language summary
The goal of this clinical trial is to learn if drug U101 works to prevent recurrent urinary tract infection (rUTI) in women (≥ 20 and \< 76 years old) with a medical history. It will also investigate the safety and the impact on the Quality of Life improvement of drug U101. The main questions it aims to answer are:
* Does the drug prevent or decrease the recurrence of urinary tract infection (UTI) during the 24-week treatment?
* Will the Quality of Life be improved during the 24-week treatment?
* What medical problems do participants have when taking drug U101?
Researchers will compare drug U101 to a placebo (a look-alike substance that contains no drug) to see if drug U101 works to prevent rUTI.
Participants will:
* Orally take drug U101 or placebo every day for 24 weeks in the main study, three times per day (TID) for 8 weeks and twice per day (BID) for 16 weeks.
* Visit the site once every 4 weeks for checkups and tests during the main study.
* be asked to enroll in extensional study (the open-label extension (OLE) with drug U101 treatment or the Safety Follow-Up Visits with no investigational product treatment) for 24 weeks after they complete the 24-week main study.
* Visit the site when the suspected UTI occurred during the main study or the extension study.
Who can participate
Age range20 Years – 75 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Provide a signed informed consent form.
✓. Non-pregnant, non-nursing females ≥ 20 and \< 76 years old.
✓. Having a history of ≥ 2 UTI events during the preceding 6 months or ≥ 3 UTI events during the preceding 12 months (including any UTI event that occurs on the date of ICF signing). At least one of the previous UTI events must have microbiologic evidence (e.g., per the investigator's judgment based on urine culture results).
✓. The last urine culture (including those conducted for suspected UTI event or retest) before the randomization has to be negative.
✓. Having a negative urinalysis result and no symptoms suggestive of a UTI on the day of randomization.
Exclusion criteria
✕. Females who are pregnant, nursing, have a desire for pregnancy or have a positive pregnancy test at screening.
✕. Women of childbearing potential who are unwilling or unable to use an acceptable contraceptive method to avoid pregnancy for the entire study period (use of spermicide is prohibited). Women of childbearing potential are defined as premenopausal females capable of becoming pregnant.
What they're measuring
1
Percentage of subjects without UTI recurrence during the 24-week main study period
Timeframe: The primary analysis will be performed at the end of the 24-week main study